Who Owns Denali Therapeutics Stock?
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 100.11%
- Institutions (% of float)
- 104.93%
- Held by insiders
- 4.59%
- Institutional holders
- 420
- Institutions 95.4%
- Insiders 4.6%
- Public and other 0.0%
Who owns Denali Therapeutics stock?
Institutional investors own about 100.1% of Denali Therapeutics's shares, spread across 420 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.59% of DNLI.
The largest institutional holders are T. Rowe Price Investment Management, Inc. (12.24%), Blackrock Inc. (8.94%) and BAILLIE GIFFORD & CO (6.94%). Together, the top 10 institutions control 52.8% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their DNLI positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of DNLI
| Institution | Shares | % Held | Change |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19.62M | 12.24% | +21.3% |
| Blackrock Inc. | 14.33M | 8.94% | +2.2% |
| BAILLIE GIFFORD & CO | 11.12M | 6.94% | -7.0% |
| Temasek Holdings (Private) Ltd | 7.01M | 4.38% | 0.0% |
| Vanguard Portfolio Management LLC | 6.76M | 4.22% | +4.3% |
| Vanguard Capital Management LLC | 6.75M | 4.21% | +7.6% |
| State Street Corporation | 6.68M | 4.17% | -5.2% |
| FMR, LLC | 4.53M | 2.83% | -0.1% |
| Geode Capital Management, LLC | 4.04M | 2.52% | +1.6% |
| Goldman Sachs Group Inc | 3.75M | 2.34% | -9.7% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of DNLI
| Fund | Shares | % Held |
|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 4.97M | 3.10% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.29M | 2.68% |
| iShares Trust-iShares Russell 2000 ETF | 3.81M | 2.38% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.10M | 1.93% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.06M | 1.91% |
| VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 2.68M | 1.67% |
| SmallCap World Fund Inc | 2.50M | 1.56% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2.33M | 1.45% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.78M | 1.11% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.73M | 1.08% |
Frequently asked questions
Who is the largest shareholder of Denali Therapeutics?
T. Rowe Price Investment Management, Inc. is the largest institutional shareholder of DNLI, owning 12.24% of shares outstanding (19.62M shares) as of its latest 13F filing.
What percentage of Denali Therapeutics is owned by institutions?
Institutions own about 100.1% of DNLI shares and 104.9% of the public float.
How much of Denali Therapeutics do insiders own?
Insiders, such as officers and directors, own about 4.59% of DNLI shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.